Articles on MHC & TCR
The interaction between MHC molecules and T-cell receptors (TCRs) is central to immune system function and therapeutic design. This category highlights key developments in MHC/TCR research, immunotherapy strategies, and biotech-driven solutions.
Featured Article
TCR Therapy Targeting MAGE-A4
Recently at the 2022 CTOS Conference, Adaptimmune announced the SPEARHEAD-1 clinical trial data of its T cell receptor-engineered T cell (TCR-T) therapy, Afamitresgene autoleucel (afami-cel), for synovial sarcoma. The results showed that the overall response rate of afami-cel was 39% and the median duration of response was 50 weeks [1].
Browse articles by topic:
June 12, 2025
5 min read
March 18, 2025
10 min read
September 18, 2024
5 min read
August 20, 2024
4 min read
December 27, 2023
5 min read
September 7, 2023
1 min read
60 Hickory Drive
Waltham, MA 02451
United States